Up­dat­ed: J&J to buy In­tra-Cel­lu­lar for $14.6B in lat­est neu­ro­science bet

John­son & John­son is ac­quir­ing In­tra-Cel­lu­lar Ther­a­pies for $14.6 bil­lion in the biggest biotech M&A trans­ac­tion since 2023.

The deal sig­nals grow­ing ex­cite­ment in neu­ro­science …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER